Correction of Genetic Blood Defects by Gene Transfer
Gene therapy has been proposed as an appealing tool for introducing a normal gene into affected hematopoietic stem cells to correct their inherited defect. Theoretically, in the absence of a related human leukocyte antigen identical donor, gene therapy could be an alternative given the accessibility and the information available on the hematopoietic stem cell biology. This chapter describes the progress and limits of the gene therapy approach applied to some genetic blood defects that appear to be good targets for this strategy.
Key WordsADA Fanconi anemia gene therapy hematopoietic SCD SCID
Unable to display preview. Download preview PDF.
- Buckley RH, Schiff SE, Schiff RI, et al. Haploidentical bone marrow stem cell transplantation in human severe combined immunodeficiency. SeminHematol 1993; 30: 92–104.Google Scholar
- Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Role of inter-leukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c transduced severe combined immunodeficiency X1 bone marrow cells. Blood 1996; 88: 3901–3909.PubMedGoogle Scholar
- Lacout C, Haddad E, Sabri S, et al. A defect in hematopoietic stem cell migration explains the non-random X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome. Blood 2003; 1:1.Google Scholar
- Persons DA, Allay ER, Sawai N, et al. Successful treatment of murine ta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 2003; 102: 506–513.Google Scholar
- Rivella S, Sadelain M. Genetic treatment of severe hemoglobinopathies: The combat against transgene variegation and transgene silencing. SeminHematol 1998; 35: 112–125.Google Scholar
- Snapper SB, Rosen FS, Mizogiuti A, Slavin SGoogle Scholar
- uchi E, et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell acti-vation. Immunity 1998; 9: 81-Bunting KD,91.Google Scholar